

PRESS RELEASE

FOR IMMEDIATE RELEASE

Haitong International Successfully Completed an IPO Deal for Immunotech Biopharm

Hong Kong, 10 July, 2020 – Haitong International Securities Group Limited (“Haitong International”; 665.HK) has completed an IPO deal in Hong Kong for Immunotech Biopharm Ltd. (“IMMUNOTECH-B”; 6978.HK), for which its corporate finance team and global capital market team acted as Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager.

Immunotech Biopharm is a cellular immunotherapy biopharmaceutical company in China focusing on the research, development, and commercialization of T cell immunotherapy for over 13 years. According to the Frost & Sullivan Report, EAL® - the Core Product Candidate of Immunotech Biopharm – is the first cellular immunotherapy product in China approved for entry in to a Phase II clinical trial, and, as at the Latest Practicable Date, the only that had been approved for application in a Phase II clinical trial for solid tumour treatment. Shares of Immunotech Biopharm were successfully listed on the Hong Kong Stock Exchange today, closing at HKD 15.48, up 40.73% from its IPO price.

Haitong International has completed 21 IPOs in Hong Kong, 22 IPOs and 29 equity financing deals globally so far this year.

– END –

Disclaimer

We, Haitong International Securities Group Limited (“Haitong International” or “HTI”) have prepared this document/presentation (“Document”) for information purpose only and for restricted circulation. We have based this Document on our internal information and information available to the public from sources we believe to be reliable. While we have taken all reasonable care in preparing this Document, we do not represent the information contained in this Document is accurate or complete and we accept no responsibility for errors of fact or for any opinion expressed in this Document.

Opinions, projections and estimates reflect our assessments as of the Document date and are subject to change. We have no obligation to notify you or anyone of any such change. You must make your own independent judgment with respect to any matter contained in this Document. Neither we nor any of our affiliates or our respective directors, officers or employees will be responsible for any losses or damages which any person may suffer or incur as a result of relying upon anything stated or omitted from this Document. This Document does not create any legally binding obligations on us and/or our affiliates.

Nothing contained in this Document is intended to constitute legal, tax, securities or investment advice of any product. No information contained in this Document constitutes an offer, or a solicitation to buy or sell any product of any type or to engage in any other transaction. You should not act or refrain from acting on the basis of any content included in this Document without seeking your own professional or investment advice. This disclaimer is available in both English and Chinese, if there is any discrepancy between the two versions, the English version shall apply and prevail.

Haitong International Securities Group Limited



Haitong International Securities Group Limited (“Haitong International”; Stock Code: 665.HK), together with its subsidiaries, is an international financial institution with established presence in Hong Kong and a rapidly expanding network across the globe. It strives to serve as a bridge linking up the Chinese and overseas capital markets. The parent company of Haitong International is Haitong Securities Co. Ltd (“Haitong Securities”, Stock Code: 600837.SH; 6837.HK).

To date, Haitong International has well positioned to serve about 200,000 corporate, institutional, as well as retail and high-net worth clients worldwide. Its well-established financial services platform provides corporate finance, wealth management, asset management, institutional clients (key businesses include fixed income, currency and commodities (FICC), derivatives, institutional equities) and investments business, and a full spectrum of financial products and services. Haitong International possesses a sound risk management system that is in line with international standards. The company has been assigned a “Baa2” long-term issuer rating by Moody’s and a “BBB” long-term credit rating by Standard and Poor’s. Haitong International has a global financial servicing network covering the world’s major capital markets including Hong Kong, Singapore, New York, London, Tokyo, Mumbai, and Sydney, thereby making it to be a leading global financial institution with international competitiveness, systematic importance and brand influence.

For further information, please contact:

Haitong International Securities Group Limited

Sarah Yan

Tel : (852) 2213 8588

Email: sarah.th.yan @htisec.com